ARTIDIS

ARTIDIS is a clinical-stage health technology company that has developed what it describes as the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The approach rests on a proprietary nanotechnology platform built around atomic force microscopy: by measuring the mechanical properties of tumours and their microenvironment, it aims to reveal metastatic potential and distinguish aggressive cancer cells. The measurement is designed to return actionable insights within hours and to preserve tissue integrity for downstream standard-of-care pathology analysis.

The company's second product, ARTIDISNET, is a digital platform that integrates different types of clinical data to help physicians shorten the diagnostic process and design personalised cancer treatment plans. Together the two products span the technical domains the company works in: nanomechanical biomarker analysis, biomechanics and cancer mechanobiology, computational diagnostics, clinical data integration and digital health, with a stated focus on translating laboratory nanotechnology into routine clinical use.

ARTIDIS is headquartered in Basel, Switzerland, and also operates in the USA, Spain and Croatia. It works across healthcare, oncology and cancer diagnostics, clinical diagnostics, digital health and medical devices. Founding year, team size and funding details are not disclosed.